One of the consensus groups on acromegaly recently recommended drug treatment combining a long-acting SSA and pegvisomant in patients in whom GH and IGF-1 levels did not decrease with somatostatin agonists alone (around 50% of cases) [13]. The gene discussed is IGF1; the disease is acromegaly.